Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy (nasal)

ABSTRACT: Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy (nasal)

PROVIDER: PRJNA849422 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy (nasal)

Project description:The Gauging Response in Allergic Rhinitis to Sublingual and Subcutaneous Immunotherapy (GRASS) study was a randomized, double-blind, placebo-controlled trial of individuals with timothy grass allergy who received 2 years of placebo, subcutaneous (SCIT), or sublingual immunotherapy (SLIT) and were followed for a total of 3 years. Here we utilized longitudinal transcriptomic profiling of nasal brush and peripheral blood mononuclear cell (PBMC) samples after allergen provocation collected in the GRASS study to uncover airway and systemic expression pathways mediating responsiveness to immunotherapy.

2023-12-31 | GSE206149 | GEO

Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy (PBMC)

2023-12-31 | GSE206151 | GEO

Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy

Project description:Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy

| PRJNA849416 | ENA

Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy (PBMC)

Project description:Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy (PBMC)

| PRJNA849421 | ENA

Expression data from patients that has received grass pollen sublingual immunotherapy treatment for two years.

Project description:Prevalence and severity of allergic diseases have increased worldwide. To date, respiratory allergy phenotypes are not fully characterized and, in addition, the mechanisms underlying sublingual immunotherapy (SLIT) are still unknown. We have used microarrays to understand the underlying mechanisms of SLIT using samples of patients under grass pollen SLIT at different timepoints (T0-before SLIT and T2-two years of treatment, Active or Placebo). We also have taken into account the sensitization of the subjects (Monosensitized patients and Polisensitiez patients)

2020-07-01 | GSE147197 | GEO

Effector cell signatures in peripheral blood after nasal allergen challenge: biomarkers of the allergic response

Project description:This study investigated temporal transcriptomic changes in response to nasal allergen challenge of titrated timothy grass pollen. This is an open single-center observational study conducted outside the pollen season. Twelve participants with seasonal allergic rhinitis underwent a control (diluent) challenge followed by nasal allergen challenge after an interval of 14 days. On each challenge day, nasal challenge with control or titrated timothy grass pollen (Aquagen, phleum pratense; ALK) was administered. Peripheral blood was collected before nasal challenge (baseline) and at 3, 6 and 24 hours following challenge. RNA was extracted from whole blood and CD4 cells for microarray experiment using Affymetrix Human Gene 1.0 ST arrays.

2013-01-16 | E-GEOD-43497 | biostudies-arrayexpress

Effect of Intradermal Immunotherapy (IDIT) injections on gene expression profiles of activated T cells derived from skin biopsy explants

Project description:A Randomized, Placebo-Controlled Trial of Intradermal Allergen Immunotherapy for Grass Pollen Allergy Background: Repeated intradermal injection of grass pollen (nanograms of allergen) suppresses allergen-induced cutaneous late phase responses, in keeping with effects of conventional high dose subcutaneous and sublingual immunotherapy. We evaluated the efficacy and safety of grass pollen intradermal immunotherapy for treatment of allergic rhinitis.Methods: We randomly assigned 93 adults with grass pollen allergic rhinitis to receive 7 pre-seasonal Intradermal allergen immunotherapy injections (containing 7 ng of Phl p 5 major allergen) or histamine control. The primary end point was daily combined symptom-medication scores during the 2013 pollen season. Skin biopsies were taken after the pollen season following an intradermal allergen challenge. Cutaneous late phase responses were measured 4 and either 7, 10 or 13 months post-treatment. Results No difference in the primary endpoint was observed between treatment arms (median difference, 14; 95% confidence interval [CI], -172.5 to 215.1; P=0.80). Amongst secondary endpoints, nasal symptoms measured with daily scores (median difference, 35; 95% CI, 4.0 to 67.5; P=0.03) and visual-analogue scales (median difference, 53; 95% CI, -11.6 to 125.2; P=0.05) were higher in the intradermal treatment group. Intradermal immunotherapy increased serum Phl p-specific IgE (P=0.001) compared to the control arm and T cells cultured from biopsies showed higher and lower surface of surface markers for Type 2 (P=0.04) and Type 1 (P=0.01) T-helper cells, respectively, Interleukin-5 was differentially expressed by microarray (P=0.03). Late phase responses were still inhibited 7 months after treatment (P=0.03) but not at 10-13 months. Conclusions Grass pollen intradermal allergen immunotherapy was not clinically effective but resulted in immunological priming and worsening of allergic rhinitis symptoms.

2017-06-23 | GSE72324 | GEO

Effector cell signatures in peripheral blood after nasal allergen challenge: biomarkers of the allergic response

Project description:This study investigated temporal transcriptomic changes in response to nasal allergen challenge of titrated timothy grass pollen.

2013-01-16 | GSE43497 | GEO

Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-12-31 | GSE206152 | GEO

Expression data from patients that has received grass pollen sublingual immunotherapy treatment for two years.

Project description:Expression data from patients that has received grass pollen sublingual immunotherapy treatment for two years.

| PRJNA613317 | ENA